News By Tag Industry News News By Place Country(s) Industry News
| Implementing a Therapeutic Hypothermia Program For Post-Cardiac Arrest in Acute Care HospitalsThe results of a survey of all 73 acute care hospitals in New Jersey evaluating the adoption and implementation of therapeutic hypothermia from 2004-2011 are published in Therapeutic Hypothermia and Temperature Management.
Therapeutic hypothermia (TH) involves reducing the body temperature to below normal levels for a prolonged period to minimize the potential damage caused by traumatic or ischemic injury that reduces blood flow to the tissues. Factors contributing to the initially slow and more recently accelerated implementation of TH in New Jersey hospitals are described by Derek DeLia and colleagues from Rutgers University (New Brunswick, NJ), University of Alabama at Birmingham, Saint Barnabas Medical Center (Livingston, NJ), and Newark Beth Israel Medical Center (Newark, NJ). The authors discuss the wide variation observed in the criteria for patient selection for TH across hospitals and the impact that variations in TH use can have on patient care in the article “Post-Cardiac Arrest Therapeutic Hypothermia in New Jersey Hospitals: Analysis of Adoption and Implementation.” “This communication is important because it focuses on the need of continued adoption and utilization of therapeutic hypothermia targeting cardiac arrest,” says W. Dalton Dietrich, PhD, Editor-in-Chief of the Journal and Kinetic Concepts Distinguished Chair in Neurosurgery, Professor of Neurological Surgery, Neurology and Cell Biology and Anatomy, University of Miami Leonard M. Miller School of Medicine. “It is hoped that this journal will continue to provide guidance as more hospitals and treating physicians use this beneficial treatment in limiting the devastating consequences of brain injury.” About the Journal Therapeutic Hypothermia and Temperature Management provides a strong multidisciplinary forum to advance the understanding of therapeutic hypothermia. Novel findings from translational preclinical investigations as well as clinical studies and trials are featured in original articles, state-of-the- About the Publisher Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Neurotrauma. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||